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Stress-kinaseAn increased reactive oxygen species (ROS) production and apoptosis rate have been associated with several
disorders involved in cobalamin metabolism, including isolated methylmalonic aciduria (MMA) cblB type
and MMA combined with homocystinuria (MMAHC) cblC type. Given the relevance of p38 and JNK kinases in
stress-response, their activation in ﬁbroblasts from a spectrum of patients (mut, cblA, cblB, cblC and cblE) was
analyzed revealing an increased expression of the phosphorylated-forms, specially in cblB and cblC cell lines
that presented the highest ROS and apoptosis levels. To gain further insight into the molecular mechanisms
responsible for the enhanced apoptotic process observed in cblB and cblC ﬁbroblasts, we evaluated the
expression pattern of 84 apoptosis-related genes by quantitative real-time PCR. An elevated number of pro-
apoptotic genes were overexpressed in cblC cells showing a higher rate of apoptosis compared to cblB and
control samples. Additionally, apoptosis appears to be mainly triggered through the extrinsic pathway in
cblC, while the intrinsic pathway was primarily activated in cblB cells. The differences observed regarding the
apoptosis rate and preferred pathway between cblB and cblC patients, who both built up methylmalonic acid,
might be explained by the accumulated homocysteine in the cblC group. The loss of MMACHC function in
cblC patients might be partially responsible for the oxidative stress and apoptosis processes observed in these
cell lines. Our results suggest that ROS production may represent a genetic modiﬁer of the phenotype and
support the potential of using antioxidants as a novel therapeutic strategy to improve the severe neurological
outcome of these rare diseases.r “Severo Ochoa”, Laboratorio
Madrid, 28049 Madrid, Spain.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial respiratory chain generates free radicals, also known
as reactive oxygen species (ROS) which are produced in physiological
and pathological conditions. ROS are molecules or ions with unpaired
electrons (OH− and O2−) which are neutralized by endogenous
antioxidant defense systems that reduce their formation or promote
their inactivation by the activity of several proteins, such as superoxide
dismutase and catalase [1]. Reactive species are necessary for normal
cell function, serving as signal molecules for important physiological
roles; however when they are produced at high levels or when the
antioxidant defenses are deﬁcient, ROS may cause damage to the cells
representing a fundamental mechanism of human disease [2]. In most
cases, the deleterious effect of ROS is a function of intracellular cell-
death activation [3]. Apoptosis is a form of cell suicide that plays an
important role in development and maintenance of tissue homeostasisin multicellular organisms [4]. The apoptosis pathways can be broadly
grouped into two main categories: (1) the extrinsic or receptor-
mediated pathwaywhich involves ligand-induced aggregation of death
receptors resulting in the activation of pro-apoptotic caspase-8 and
caspase-10; and (2) the intrinsic or mitochondrial-mediated pathway
where the fate of the cell is determined at themitochondrial membrane
level by the balance between pro-apoptotic and anti-apoptotic
members of the BCL-2 family [5,6]. In humans, several lines of evidence
point toward oxidative damage and defects in programmed cell death
on a number of pathologies, including autoimmunity, cancer, mito-
chondrial and neurodegenerative diseases [7–11].
Alterations in mitochondrial function caused by inhibition of
mitochondrial energy metabolism also exert a relevant role in the
pathophysiology of a number of inherited metabolic disorders (IMD),
such as maple syrup urine disease, propionic acidemia and methyl-
malonic aciduria (MMA) among others [12,13]. Vitamin B12 (cobal-
amin, Cbl), in the form of the cofactors adenosylcobalamin (AdoCbl)
and methylcobalamin (MeCbl), is required by the mitochondrial
enzyme methylmalonyl-CoA mutase (MUT) and by the cytosolic
enzymemethionine synthase (MTR), respectively. Inherited disorders
of Cbl metabolism are rare conditions caused by deﬁciencies in MUT,
MTR or methylmalonyl-CoA epimerase enzymes, or alternatively by
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transport or cofactors' synthesis deﬁning different complementation
groups. The cblA (MIM#251100), cblB (MIM# 251110), cblD variant
2 (MIM#277410) and mut (MIM#251000) disorders cause isolated
MMA; cblC (MIM#277400), cblD variant 1 (MIM#277410) and cblF
(MIM#277380) cause combined MMA with homocystinuria
(MMAHC); and cblE (MIM#236270) and cblG (MIM#250940)
cause isolated homocystinuria [14,15]. Patients belonging to the
cblB group present defects in theMMAB gene (MIM#607568) which
encodes a mitochondrial enzyme member of the PduO family of
cobalamin adenosyltransferases: ATP:cob(I)alamin adenosyltrans-
ferase (ATR) implicated in AdoCbl metabolism [16]. The cblC type
group is the most common genetic defect in Cbl metabolismwhich is
associated with defects in the MMACHC gene (MIM#609831),
affecting both AdoCbl and MeCbl metabolism [17]. The cytosolic
MMACHC gene product is responsible for early processing of both
CNCbl (decyanation) and alkylcobalamins (dealkylation) in mam-
malian cells [18].
Despite continuous attempts during the last 20 years to improve
therapy for these diseases, the overall outcome of MMA and MMAHC
patients remains disappointing; many of them still present severe
symptoms that include psychomotor retardation and long-term
neurological damage [19–21]. Although three pathomechanisms
have been proposed to explain the neurological damage (the “toxic
metabolite hypothesis”, synergistic inhibition of mitochondrial ener-
gy metabolism and dicarboxylic acids and the “trapping hypothesis”)
[22], the mechanisms underlying the pathophysiology of MMA and
MMAHC are far from being understood. Data from our laboratory
support the implication of oxidative stress in the pathophysiology of
these disorders [23–25]. Fibroblasts from cblB and cblC patients
showed a signiﬁcant increase in intracellular ROS content. In addition,
the mitochondrial oxidative stress marker, manganese superoxide
dismutase (MnSOD), was overexpressed in patients' cell lines in
comparison with controls suggesting a cellular response to intrinsic
ROS stress. Moreover, patients' cells showed a higher rate of apoptosis
compared to controls. Our results also indicate that this process
primarily involves the mitochondrial/caspase-dependent pathway in
patients with cblB disorder [24]. In addition to our observations,
altered mitochondrial morphology and respiratory chain dysfunction
have been recently described in a background-modiﬁed mut-
knockout mouse and in the liver from a mut MMA patient revealing
mitochondrial dysfunction and glutathione depletion [26]. Further-Table 1
Molecular and clinical description of patients with defects in Cbl metabolism analyzed in th
Patient no. Gene affected (complementation group) Genotype
1 MMAA (cblA) p.Q133X/p.Q133X
2 MMAA (cblA) p.E199fs/p.E199fs
3 MMAB (cblB) p.R186W/p.R186W
4 MMAB (cblB) p.I96T/p.S174fs
5 MMAB (cblB) p.I96T/p.S174fs
6 MMACHC (cblC) p.R91KfsX14/p.R91KfsX
7 MMACHC (cblC) p.R91KfsX14/p.R91KfsX
8 MMACHC (cblC) p.R91KfsX14/p.R91KfsX
9 MMACHC (cblC) p.R91KfsX14/p.R91KfsX
10 MMACHC (cblC) p.R91KfsX14/p.R91KfsX
11 MMACHC (cblC) p.R91KfsX14/p.R91KfsX
12 MMACHC (cblC) p.R91KfsX14/p.R153X
13 MMACHC (cblC) p.R91KfsX14/c.81+2T
14 MMACHC (cblC) p.R91KfsX14/p.R189S
15 MMACHC (cblC) p.R91KfsX14/p.M1L
16 MMACHC (cblC) p.R91KfsX14/p.R161X
17 MUT (mut0) p.V583fs/c.1957-891CN
18 MTRR (cblE) p.V56M/p.V56M
19 CBS p.T191M/p.T191M
EO, early onset (less than 1 year of age); LO, late onset (older than 1 year of age); A, alive; D,
NA, not available; y, year; m, month; d, day. Patients 4 and 5 are siblings; P4 presented a fa
a P No., patient number in each reference is indicated.more, there is supporting data from different samples, such as tissues
and cellular extracts from treated laboratory animals [27–29] and
urinary samples from MMA patients [12] that correlate oxidative
stress with this human disease.
In support of our previous observations and given the high interest
of this topic, we have investigated the activation of p38 and JNK stress
kinases by immunoblotting along with the expression proﬁling of a
set of genes relevant to the apoptosis pathways by PCR array in
patients' cells with defects in Cbl metabolism. The combination of
these powerful approaches has allowed the identiﬁcation of genes
speciﬁcally related to the mechanisms of stress response in patients
with cblB and cblC disorders contributing to elucidate the pathophys-
iology of these rare metabolic diseases.
2. Materials and methods
2.1. Samples
Fibroblast cell lines from 19 patients were used in this study,
including 2 cblA (P1, P2), 3 cblB (P3–P5), 11 cblC (P6–P16), 1 cblE
(P18) and 1mut0 (P17) patients with defects in Cbl metabolism, and
1 individual with defects in cystathionine β-synthase (CBS) which
presents homocystinuria and was used as a control (P19). None of
the patients reported herein were referred from the newborn
screening metabolic program; all of them were clinically diagnosed
after presenting a metabolic crisis. Patients were referred from
clinics to be biochemically and/or genetically diagnosed at Centro de
Diagnóstico de Enfermedades Moleculares in Madrid. Relevant
clinical and molecular data, as well as references about individual
patients included in this study are provided in Table 1. Skin
ﬁbroblasts from ﬁve controls (GM09503, GM08333, GM08429,
GM08680 and GM03348) were obtained from Coriell Cell Reposito-
ries (NJ, USA). Fibroblast cultures were established from patients'
and controls' skin biopsies and cultivated according to standard
procedures [24]. Ethical approval for the use of human samples in the
study was granted by the Ethics Committee of the Universidad
Autónoma de Madrid.
2.2. Expression of human MMACHC cDNA in ﬁbroblast cells
Wild-type MMACHC cDNA was generated by RT-PCR from total
RNA extracted from normal human ﬁbroblasts and conﬁrmed byis work.
Onset Outcome Referencea (P No.)
EO A 18 y; DD [54] (P20)
EO A 12 y; DD; H [54] (P25)
EO D 10 d [54] (P31)
LO D 4 y [35] (P2)
A [35] (P3)
14 EO D 5 m [25] (P4)
14 EO D 4 m [25] (P5)
14 EO NA [25] (P6)
14 EO A 8 y; DD; DVA; behavior problems [25] (P7)
14 EO D 6 m [25] (P32)
14 EO A 8 y; DD; DVA [25] (P35)
EO D 3 y [25] (P40)
NG EO A 24 m; DD; DVA [25] (P41)
LO A 18 y; asymptomatic [25] (P43)
EO A 5 y; DD; DVA; S [25] (P44)
EO A 8 y; DD; DVA [25] (P47)
A EO D 5 y [55]
EO A 25 m, DD Not reported
NA NA Not reported
died; DD, developmental delay; DVA, decreased visual acuity; H, hypotonia; S, seizures;
tal crisis and suddenly died at 4 years of age; P5 is clinically normal.
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vector (Promega, Madison, WI, USA), and then subcloned into a
bicistronic green ﬂuorescent protein (GFP)-expressing MIGR1-
retroviral vector [30]. Retroviruses were generated by transient co-
transfection with the retroviral vector, and pGagPol and VSVG
plasmids using Fugene 6 (Roche Applied Science, Mannheim,
Germany) in 293T/17 cells. Retroviruses encoding both GFP and
MMACHC proteins, or GFP alone were used to infect ﬁbroblasts from
patients P6 (cblC), P7 (cblC), P4 (cblB) and a control cell line. The
control cell line was used as an internal control of the assay. Cells
were selected for GFP expression using ﬂuorescence activating cell
sorting (FACS) on a FACSCVantage SE cell sorter (BD Biosciences, San
Jose, CA, USA). MMACHC activity was indirectly measured by the
analysis of radioactivity incorporation from [1-14C] propionate into
acid-precipitable material in infected ﬁbroblasts [31]. Propionate
oxidation is catalyzed by two mitochondrial enzymes: the biotin-
dependent propionyl-CoA carboxylase and the AdoCbl-dependent
MUT. Patients with defects in MMAB and MMACHC genes exhibit
deﬁcient propionate incorporation since their gene products are
involved in AdoCbl synthesis.
2.3. RT2 Proﬁler™ PCR Array human apoptosis
Total RNA was isolated from ﬁbroblasts using MagNA Pure
Compact RNA Isolation kit and MagNA Pure Compact instrument
(Roche Applied Science). Samples were quantitated spectrophoto-
metrically at 260 nm using the Nanodrop ND-1000 photometer
(Thermo Scientiﬁc, Wilmington, MA, USA).
Real-time PCR reactions were analyzed in total RNA using the
Human Apoptosis RT2 Proﬁler™ PCR Array (SuperArray Bioscience
Corporation, Frederick, MD, USA) according tomanufacturer's protocol.
Brieﬂy, cDNA was prepared from 750 ng total RNA using RT2 PCR array
ﬁrst strand kit (SuperArray Bioscience). cDNA was diluted by adding
RNase-free water. The PCR was carried out using a LightCycler® 480
apparatus (Roche Applied Science). For one 96-well-plate of the PCR
array, 2550 μl of PCR master mix containing 2× SuperArray RT2 qPCR
Master Mix and 102 μl of diluted cDNA were prepared, and aliquots of
25 μl were added to each well. Universal cycling conditions (10 min at
95 °C, 15 s at 95 °C, 1 min 60 °C for 40 cycles) were applied.
The humanApoptosis RT2 Proﬁler PCRArray proﬁles the expression
of 84 key genes involved in apoptosis or programmed cell death. The
array includes the TNF ligands and their receptors; members of the
BCL-2, caspase, IAP, TRAF, CARD, death domain, death effector domain,
and CIDE families; as well as genes involved in the p53 and ATM
pathways (http://www.sabiosciences.com/rt_pcr_product/HTML/
PAHS-012A.html).
2.4. Data normalization and analysis
Several patients' ﬁbroblasts from cblB and cblC complementation
groups were used to perform the PCR array. cblB group comprises
patients number 4 and 5 (pool of cblB patients), cblC group includes
patients 6, 7, 9, 12, 13 and 15 (pool of cblC patients); and control
group includes GM08429, GM08680, GM03348 and GM09503 (pool
of controls). Five endogenous control genes, beta-2-microglobulin
(B2M), hypoxanthine phosphoribosyltransferase 1 (HPRT1), ribo-
somal protein L13a (RPL13A), glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and β-actin (ACTB), present on the PCR array were
used for normalization. Relative quantiﬁcation of apoptotic gene
expression was analyzed by the comparative threshold cycle (Ct)
method [32,33]. CT was deﬁned as 35 for the ΔCT calculation when the
signal was below detectable limits. ΔCT was calculated as the
difference in CT between the target gene and the average of
housekeeping genes for each sample. Then, the average of the ΔCT
of the cblB patients' cell lines was calculated and named ΔCT (pool of
cblB patients), the same formula was applied to the cblC cell lines andto the control cell lines that were calledΔCT (pool of cblC patients) and
ΔCT (pool of controls), respectively. The following formula was
applied to calculate the relative amount of transcripts in patients'
groups respect to controls: ΔΔCT (cblB)=ΔCT (pool of cblB patients)
−ΔCT (pool of controls) for each gene; andΔΔCT (cblC)=ΔCT (pool of
cblC patients)−ΔCT (pool of controls) for each gene. The fold-change
for each gene in both groups of patients relative to the control group
was calculated as 2−ΔΔCT. Changes in gene expression between
patients and controls were illustrated as a fold-increase/decrease.
Using cut-off criteria, a 1.5-fold induction or a 0.6-fold repression of
gene expression was considered to be of biological relevance. Results
are represented as cblB-fold change and cblC-fold-change in Table 2.
For the infected P6 (cblC), P7 (cblC) and P4 (cblB) patients'
ﬁbroblasts, ΔΔCT was calculated as ΔCT (of each cell line expressing
GFP-MMACHC)−ΔCT (of each cell line expressing GFP). The fold-
change for each gene in P6, P7 and P4 expressing GFP-MMACHC
relative to the same cell line expressing GFP was calculated as 2−ΔΔCT.
2.5. Western Blot analysis
A total of 4×105 ﬁbroblast cells of each line were placed in 6-well
plates 24 h prior protein analysis. Cells were lysatedwith 50 μl/well of
ice-cold lysis buffer (1% Triton X-100, 10% glycerol, 150 mM NaCl,
10 mM Tris–HCl pH 7.5, protease inhibitor cocktail tables (Roche
Applied Science), 10 mM sodium ﬂuoride, 1 mM sodium pyrophos-
phate, 1 mM sodium orthovanadate and 1 mM DTT). After centrifu-
gation, protein content from supernatants was determined by
Bradford method (Bio-Rad Laboratories, Hercules, CA, USA) using
BSA as standard. Samples were loaded onto 10% or 4–12% NuPAGE
Novex Bis–Tris mini gels (Invitrogen, Carlsbad, CA, USA) and blotted
onto nitrocellulose membranes using iBlot Dry Blotting system
(Invitrogen). Poinceau staining was used to verify equal amounts of
protein loads. Western blotting was carried out using phospho-p38
MAP kinase (Thr180/Tyr182) polyclonal antibody (Cell Signaling
Technology, Inc., Danvers, MA, USA), p38 polyclonal antibody (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), phospho-SAPK/JNK
(Thr183/Tyr185) polyclonal antibody (Cell Signaling Technology,
Inc.), JNK2 polyclonal antibody (Cell Signaling Technology, Inc.), BCL-
2 mouse monoclonal antibody (Santa Cruz Biotechnology, Inc.) and
NOL-3 polyclonal antibody (Santa Cruz Biotechnology, Inc.). Second-
ary antibodies were used as IgG-horseradish peroxidase conjugated
and were detected by the Enhanced Chemiluminescence System (GE
Healthcare, Berkshire, UK). Protein quantiﬁcation was performed
using a calibrated densitometer GS-800 (Bio-Rad Laboratories).
2.6. Apoptosis studies
Assays were performed when cultures reached 75–85% of conﬂu-
ence. Controls and patients' ﬁbroblast cell lines (P4, P5, P6, P7, P9, P12,
P13 and P15) ranged between 7 and 10 passages. The cultures were
treated with different stimulus (all of them from Sigma-Aldrich, St.
Louis, MO): i) 2 μM staurosporine for 1 h; ii) 20 ng/ml TNF-α and
25 μg/ml cycloheximide (CHX) for 20 h; and iii) 20 mM Tiron®
(4,5-Dihydroxy-1,3-benzenedisulfonic acid disodium salt) for 20 h.
Apoptotic cells were identiﬁed and quantitated by ﬂow cytometry
using the annexin V-DY634 apoptosis detection kit (Immunostep
Research, Salamanca, Spain) as previously described in [25].
3. Results
3.1. p38 MAPK/JNK stress signaling pathway
ROS can activate several signaling pathways in cells including
those that regulate cell death. One goal of this workwas to analyze the
activation of two proteins belonging to the mitogen-activated protein
kinase (MAPK) superfamily, p38 kinase and Jun N-terminal kinase
Table 2
Fold-change proﬁle of apoptotic genes in ﬁbroblasts from patients with cblB and cblC disorders.
GeneBank accession Description Gene symbol cblB-fold change cblC-fold change
Pro-apoptotic genes
TNF ligand family
NM_000595 Lymphotoxin alpha (TNF superfamily member 1) LTA 1.75 2.1
NM_000594 Tumor necrosis factor (TNF superfamily member 2) TNF 1.4 1.9
NM_003810 Tumor necrosis factor (ligand) superfamily member 10 TNFSF10 1.7 1.54
TNF receptor family
NM_001250 Tumor necrosis factor receptor superfamily, member 5 TNFRSF5 0.37 1.3
NM_001065 Tumor necrosis factor receptor superfamily, member 1A TNFRSF1A 0.61 1.55
NM_003790 Tumor necrosis factor receptor superfamily, member 25 TNFRSF25 0.48 5.35
NM_003844 Tumor necrosis factor receptor superfamily, member 10A TNFRSF10A 0.77 1.79
NM_003842 Tumor necrosis factor receptor superfamily, member 10B TNFRSF10B 0.47 0.8
NM_014452 Tumor necrosis factor receptor superfamily, member 21 TNFRSF21 0.4 1.38
NM_001242 CD27 molecule CD27 1.67 2.1
NM_001561 Tumor necrosis factor receptor superfamily, member 9 TNFRSF9 1.44 2.12
NM_002342 Lymphotoxin beta receptor (TNFR superfamily member 3) LTBR 1.76 1.74
Bcl-2 family
NM_003806 Harakiri, BCL2 interacting protein HRK 17.6 7.1
NM_001197 BCL2-interacting killer (apoptosis inducing) BIK 1.4 1.8
NM_004324 BCL2-associated X protein BAX 0.9 1.9
NM_014739 BCL-2 associated transcription factor 1 BCLAF1 0.6 0.56
Caspase family
NM_033292 Caspase 1, apoptosis-related cysteine peptidase CASP1 1.79 1.25
NM_004346 Caspase 3, apoptosis-related cysteine peptidase CASP3 0.78 0.52
NM_001227 Caspase 7, apoptosis-related cysteine peptidase CASP7 0.8 1.51
NM_001229 Caspase 9, apoptosis-related cysteine peptidase CASP9 1.61 1.3
NM_001230 Caspase 10, apoptosis-related cysteine peptidase CASP10 1.32 1.59
CARD family
NM_006092 Nucleotide-binding oligomerization domain containing 1 NOD1 1.74 2.01
NM_001160 Apoptotic peptidase activating factor 1 APAF1 1.64 1.68
NM_014959 Caspase recruitment domain family, member 8 CARD8 0.4 0.93
Death domain
NM_004938 Death-associated protein kinase 1 DAPK1 0.5 1.1
Death effector domain
NM_003824 Fas (TNFRSF6)-associated via death domain FADD 0.42 0.8
CIDE domain family
NM_001279 Cell death-inducing DFFA-like effector a CIDEA 1.4 1.7
NM_014430 Cell death-inducing DFFA-like effector b CIDEB 0.9 1.93
p53 family
NM_005426 Tumor protein p53 binding protein, 2 TP53BP2 0.4 0.74
NM_000546 Tumor protein p53 (Li-Fraumeni syndrome) TP53 0.4 0.49
Anti-apoptotic genes
Bcl-2 family
NM_000633 B-cell CLL/lymphoma 2 BCL2 0.94 1.7
NM_021960 Myeloid cell leucemia sequence 1 (BLC2-related) MCL1 1.6 1.86
NM_004323 BCL2-associated athanogene BAG1 2.12 1.9
NM_004049 BCL2-related protein A1 BCL2A1 2.01 1.82
NM_138578 BCL2-like 1 BCL2L1 0.9 1.59
IAP family
NM_004536 NLR family, apoptosis inhibitory protein NAIP 0.7 2.08
NM_001165 Baculoviral IAP repeat-containing 3 BIRC3 0.68 1.51
NM_001167 Baculoviral IAP repeat-containing 4 BIRC4 0.75 1.54
TRAF family
NM_021138 TNF receptor-associated factor 2 TRAF2 0.39 2.1
NM_003300 TNF receptor-associated factor 3 TRAF3 0.57 1.81
NM_004295 TNF receptor-associated factor 4 TRAF4 0.53 2.18
CARD family
NM_003946 Nucleolar protein 3 (apoptosis repressor with CARD domain) NOL3 1.75 1.8
Death effector domain
NM_003879 CASP8 and FADD-like apoptosis regulator CFLAR 0.54 1.61
Other genes
NM_005163 V-akt murine thymoma viral oncogene homolog 1 AKT1 0.57 1.77
NM_004333 V-raf murine sarcoma viral oncogene homolog B1 BRAF 1.2 1.79
NM_016561 Bifunctional apoptosis regulator BFAR 0.6 0.52
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detected in MMA patients [24,25]. We have analyzed the expression
of the activated forms of p38 and JNK proteins by immunoblotting in a
spectrum of patients' cell lines with defects in Cbl metabolism
belonging to different complementation groups (mut, cblA, cblB, cblC
and cblE) and in a patient's cell line with defects in CBS (Table 1). The
expression pattern of phosphorylated p38 and JNK proteins was
individually normalized by the protein expression of total p38 andtotal JNK proteins which include both the phosphorylated and non-
phosphorylated forms. Thus, an increased expression of phospho-p38
has been detected in the patients' cell lines which had the highest ROS
levels: cblB (P4) (Fig. 1A), cblC (P7, P9, P12, P15 and P13) (Fig. 1A),
cblE (P18) (Fig. 1B) and the cell line with defects in CBS (P19)
(Fig. 1B). Phospho-JNK was overexpressed in cblB ﬁbroblasts (P4 and
P5) (Fig. 1A and B) as well as in cblC cell lines (P7, P9, P12, P15 and
P13) (Fig. 1A) with the highest ROS levels. A group of cblC cell lines,
Fig. 1. Analysis of phosphorylated p38 and JNK stress-activated protein kinases
expression in patients' ﬁbroblasts. (A, B and C) Equal amounts of controls (GM09503
(C1), GM08333 (C2) and GM08680 (C4)) and patients' samples (Table 1) were loaded
(40 μg of total cell lysates) and subjected to immunoblotting with anti-phosphorylated
p38 and anti-phosphorylated JNK antibodies. The stripped blots were reprobed with
total anti-p38 and total anti-JNK antibodies as evidence of the equivalent amounts of
protein loaded in each lane. The results in each case are representative of at least three
independent experiments. Patients along with the complementation groups they
belong to are depicted in the upper panels. C: control; P: patient.
Table 3
Gene expression categories in cblB and cblC cell lines.
cblB cblC
Pro-apoptotic genes
Overexpressed
genes
HRK, LTA, CD27, LTBR, NOD1,
TNFSF10, CASP9, CASP1,
APAF1
HRK, LTA, CD27, LTBR, NOD1,
CASP10, TNFSF10, APAF1,
TNFRSF1A, TNFRSF25, CIDEB,
BAX, CASP7, TNFRSF10A, TNF,
BIK, TNFRSF9, CIDEA
Under-expressed
genes
TP53BP2, TP53, TNFRSF1A,
TNFRSF25, CARD8,
TNFRSF10B, FADD, DAPK1,
TNFRSF5, TNFRSF21, BCLAF1
TP53, BCLAF1, CASP3
Anti-apoptotic genes
Overexpressed
genes
MCL1, BAG1, BCL2A1, NOL3 MCL1, BAG1, BCL2A1, NOL3,
TRAF4, TRAF2, TRAF3, AKT1,
NAIP, BRAF, BIRC3, BIRC4,
BCL2, BCL2L1, CFLAR
Under-expressed
genes
BFAR, TRAF4, TRAF2, TRAF3,
AKT1, CFLAR
BFAR
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activation of these kinases (P14, P6, P10, P8, P11, P16) (Fig. 1C).
Quantitative densitometric analysis demonstrated a 1.5–2.5-fold
higher expression for phospho-p38 and a 1.5–1.8-fold higher
expression for phospho-JNK in half of the patients' cell lines compared
to controls (Supplementary Fig. 1). The results obtained from the p38
protein activation correlated to the ROS levels previously observed in
16 of the 19 cell lines (Pearson's correlation coefﬁcient, r=0.72);
however there was not a signiﬁcant correlation between p-JNK
expression and ROS levels probably due to the lower activation of JNK
compared to p38 which is particularly highly activated.
Given the biochemical response to hydroxocobalamin (OHCbl) in
vivo in cblC and in some cblB-affected patients and/or in vitro in
patients' cell lines [25,34,35], and the decrease in ROS levels in OHCbl-
treated cells [25], the expression pattern of stress-kinases was studied
in depth for two cblC patients (P6, P7), one cblB patient and a control
cell line supplemented with 1 μg/ml of OHCbl during 72 h. P6 and P7
cell lines were selected from the cblC group because even when they
share the same genotype they present a different kinases' activation
response. P-p38 expression was signiﬁcantly reduced in P7 (35%), and
slightly reduced in P6 (17%) and P4 (18%) ﬁbroblasts after OHCbl
treatment compared to each cell line no-treated (data not shown). Inthe case of p-JNK expression, all the three cell lines presented a
moderate reduction (P6: 27%, P7: 25% and P4: 31%). Stress-kinases
activation is overall reduced in P7 cell line, which presented high ROS
and apoptosis rate. There was no reduction in both kinases'
expression in the control cell line after OHCbl treatment. This
moderate decrease in the activation of these stress-kinases is in
accordancewith our previous studies that shown amoderate decrease
of relative ROS levels (range 10–20%) after OHCbl cell incubation [25].
3.2. Human apoptosis PCR array
In order to deepen the understanding of the apoptosis process in
these groups of disorders with defects in Cbl metabolism, we
performed a PCR array designed to determine the expression proﬁle
of a group of 84 genes, including TNF ligands and their receptors,
members of the BCL-2, caspase, IAP, TRAF, CARD, death domain, death
effector domain, CIDE families, p53 and DNA damage response, all of
which are involved in apoptosis. In this array, we have included four
controls, two patients belonging to the cblB group (P4 and P5) with
isolated MMA and six cblC patients (P6, P7, P9, P12, P13, P15) with
MMAHC that previously showed the highest ROS content and also a
high rate of apoptosis, as mentioned above.
In order to understand the implication of each gene in the
apoptosis mechanisms, we classiﬁed the genes with altered expres-
sion in two groups: i) pro-apoptotic genes and ii) anti-apoptotic
genes. We identiﬁed the altered expression of 30 genes in cblB and 37
genes in cblC cell lines (Table 2). In cblB patients, 20 pro-apoptotic
genes (9 overexpressed and 11 under-expressed), and 10 anti-
apoptotic genes (4 overexpressed and 6 under-expressed) were
detected (Table 3). In the group of cblC patients, 21 pro-apoptotic
genes (18 overexpressed and 3 under-expressed), and 16 anti-
apoptotic genes (15 overexpressed and 1 under-expressed) were
identiﬁed (Table 3). The fold-change of the expression pattern was
moderate; only 11 genes showed a fold-change rate higher than 2. The
highest overexpression, among all the genes studied in both cblB and
cblC cell lines, was the activator of apoptosis harakiri (HRK).
When comparing the relative gene expression between cblB and
cblC groups, several differences were observed. CblC cell lines
presented a higher number (18 versus 9) and a higher fold-change
(2–2.5-fold versus 1.5–1.8-fold) of overexpressed pro-apoptotic
genes than cblB cell lines (Supplementary Table 1). Most of the pro-
apoptotic genes with an increased expression in cblC ﬁbroblasts
belong to different families, such as TNF ligand and receptor families
and CASP10 among others (Table 2), which are involved in the
extrinsic or the death receptor-mediated apoptosis pathway. In
contrast, these genes were under-expressed in cblB lines (Table 3).
In addition, among the overexpressed pro-apoptotic genes in cblB cell
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mitochondrial apoptosis pathway.
In order to conﬁrm the gene expression pattern observed, a subset
of genes was selected (BCL-2 and NOL-3, the transcripts that showed
the highest expression among the anti-apoptotic-related genes) to
determine their protein expression pattern in two cblB (P3 and P4)
and in ﬁve cblC patients' cells (P7, P9, P12, P13 and P15) by
immunoblotting (Supplementary Fig. 2). Differential protein expres-
sion was consistent with the array results conﬁrming that NOL-3 and
BCL-2 are specially increased in cblC cell lines. NOL-3 protein
expression appears particularly increased in cblC ﬁbroblasts from
P7, P9, P15 and P13 patients (1.5–2-fold) (Supplementary Fig. 2A).
Finally, overexpression of BCL-2 was specially detected in the cblC cell
lines: P9, P12, P15 and P13 (2–4 fold-change) (Supplementary
Fig. 2B).
To verify if the MMACHC loss of function is related to the observed
apoptosis process, we analyzed the expression pattern of the
previously studied apoptotic genes in the same patients' ﬁbroblasts
that were selected for OHCbl study, two from the cblC group (P6, P7)
and one from the cblB one (P4), and in a control cell line, all of them
infected with wild-type MMACHC cDNA using a retroviral vector.
Function of MUT, measured by the incorporation of label from [14C]-
propionate into cellular macromolecules, was restored to nearly the
low range of control levels in infected cblC ﬁbroblasts: 85% and 51% in
P6 and P7, respectively. The radioactivity incorporation was similar in
the non-infected control cell line compared to the infected line
expressing MMACHC-GFP proteins and also GFP alone reﬂecting no
substantial change in the metabolic pathway. The MUT function was
not restored in cblB ﬁbroblasts (P4) due to the intrinsic MMAB gene
defect. Initially, in order to select which genes were up-regulated in
the non-infected cell lines, we performed an individually fold-change
comparison for each gene in the non-infected P6, P7 and P4 cells
respect to the non-infected pool of control individuals. A total of 49
different genes were up-regulated and then selected for the analysis
of the MMACHC expression effect in these cell lines which shared
some of these genes: 15 genes were up-regulated in P6, 40 in P7 and
13 in P4. The gene expression response to retroviral infection in
patients' cell lines expressing MMACHC protein is shown in Table 4.
The fold-change for each gene was calculated in each cell line
expressing MMACHC protein respect to the same cell line expressing
GFP alone; then the genes were selected based on the criteria of a 1.5-
fold induction or a 0.65-fold repression. The global result obtained in
the three cell lines showed that 27 genes were down-regulated, 3
were undetectable and 19 did not show any change in their
expression of the total of 49 genes that were previously up-regulated.
No essential changes were detected in relation to the genes that were
down-regulated in the non-infected cell lines and the genes that were
up-regulated post-infection (19 genes versus 2).
Interestingly, P7 (cblC) which showed a high activation of stress-
kinases and apoptosis rate in non-infected cells, presented the highest
number of down-regulated genes (19) along with the highest fold-
change in gene repression when MMACHC protein was expressed in
this patient's cell line. It is worth noting that the most relevant genesTable 4
Gene expression response to retroviral infection in cblC and cblB cell lines which
express MMACHC protein.
Patients Down-regulated genes Up-regulated genes
P6 (cblC) BAG3, BAK1, BAX, GADD45A, LTA, TNF,
TNFRSF10B, TRAF2
CARD8
P7 (cblC) AKT1, APAF1, BCL2A1, BAK1, BIRC2, BIRC3,
BIRC4, CARD6, CASP10, CFLAR, CIDEB, IGF1R,
DFFA, FADD, NOD1, NOL3, TNFSF10, TNFRSF10B,
TNFRSF11B
BNIP2
P4 (cblB) BAX, BCL2L1, CFLAR, CASP7 CARD8previously up-regulated in non-infected cblB and cblC groups (TNF
ligand, TNF receptor, BCL-2, caspase, CARD and CIDE families)
indicated in Table 2, were down-regulated in cblC ﬁbroblasts (P6
and P7) expressing MMACHC by retroviral infection (Table 4). Taking
into account the functional gene groupings, 19 genes down-regulated
were pro-apoptotic genes. In summary, 55% of the array gene
expression (27 genes down-regulated out of 49 total genes selected)
has been corrected when MMACHC function was partially restored.
3.3. Functional studies of cell death in response to different stimulus that
activate apoptosis pathways, and in response to ROS scavenger
To further investigate the activation of the extrinsic and intrinsic
apoptosis pathways in the different cell lines analyzed by PCR array,
ﬁbroblasts were cultured in presence of different stimulus, such as
staurosporine and TNF-α (Fig. 2). Staurosporine, an activator of the
intrinsic mitochondrial pathway [36], induced apoptosis in all the
studied cell lines (N2-fold) (Fig. 2A), specially in cblB patients (P5 and
P4) (≥3-fold) and in those cblC patients (~3-fold) which previously
presented the highest ROS and apoptosis levels [25]. On the other
hand, the extrinsic apoptosis pathway was induced using TNF-α/CHX
in a great extent in the cblC cell lines (2–3-fold) (Fig. 2B). To establish
a link between ROS production and the cell death execution, the
effects of an antioxidant were studied. Tiron®, a scavenger of
superoxide anion, was able to quench ROS production (data not
shown) and cell death (Fig. 2C). The percentages of apoptotic cells
were signiﬁcantly reduced (~50%) overall in P4 (cblB), P7 (cblC) and
P13 (cblC) cell lines which presented the highest ROS and apoptosis
levels.
4. Discussion
ROS play an important role in the regulation of cellular mechan-
isms leading to the activation of essential signaling proteins, such as
p38 and JNK which belong to the mitogen-activated protein kinases
(MAPKs) family [37]. Activation of these signaling pathways has been
suggested to mediate neuronal apoptosis in Alzheimer's disease,
Parkinson disease and amyotrophic lateral sclerosis [38]. One of the
main goals of this work was to study the activation of p38 and JNK
kinases which revealed a stimulation of these activated stress-sensing
pathways, specially in those patients that presented higher levels of
intracellular ROS (cblB, cblC, cblE and CBS-deﬁcient patient). The fact
that ﬁbroblasts from cblC patients with MMAHC, cblE with homo-
cystinuria and the CBS deﬁcient patient with homocystinuria present
the highest ROS level [25] and phospho-p38 activation, suggests that
homocysteine might play a relevant role in stress-response, as it is
indicated below. Mitochondria are inﬂuenced by pro-apoptotic signal
transduction through the JNK pathway [39], a higher expression of
phosphorylated JNK protein in cblB cell lines compared to the other
groups and control cell lines suggests that the intrinsic or mitochon-
drial pathway is its preferred apoptosis path. These promising results
will be followed up with further studies focused on upstream
components of the signaling pathways that culminate in the
activation of p38 and JNK proteins due to these metabolic disorders.
In order to conﬁrm the differences observed regarding the
apoptosis process in both cblB and cblC cell lines, we performed a
PCR array designed to determine the expression proﬁle of a group of
apoptotic genes. Our results provide clear evidence that cblB and cblC
cell lines do not share a common apoptotic pathway given the low
degree of similarity in their apoptotic gene expression. In cblC
patients' ﬁbroblasts, the induction of apoptosis has been essentially
maintained by the activation of the death receptor-mediated
apoptotic pathway. These cell lines showed a highly up-regulation
of components of the extrinsic pathway, the majority of them belong
to the TNF ligand (LTA, TNF, TNFSF10) and receptor families
(TNFRSF5, TNFRSF1A, TNFRSF25, TNFRSF10A, TNFRSF21, CD27,
Fig. 2. Detection of annexin V-apoptosis in control and patients' ﬁbroblasts by ﬂow cytometry. (A) Staurosporine treatment. Cells were incubated with 2 μM of staurosporine for 1 h.
(B) TNF-α and CHX treatment. Fibroblasts were incubated with 20 ng/ml of TNF-α and 25 μg/ml of CHX for 20 h. (C) Antioxidant treatment. Cell lines were incubated with 20 mM of
Tiron® for 20 h. Results are expressed as apoptotic positive cells in stimulus-treatedﬁbroblasts relative to the corresponding untreated cells.Data representmean±SDof two independent
experiments, each one performed by triplicated (*Pb0.05; **Pb0.01). Patients along with the complementation groups they belong to are depicted in the ﬁgure. C: control; P: patient.
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down-regulated in cblB patients' ﬁbroblasts. On the other hand, the
up-regulation of CASP9 has been mainly observed in ﬁbroblasts from
patients with cblB disorder, as we previously observed by ﬂow
cytometry [24]. CASP9 activation along with the induction of
phosphorylated JNK kinase suggest the involvement of the mitochon-
drial pathway overall in the cblB group. The overexpression of
additional genes has also been detected in both cblB and cblC patients'
ﬁbroblasts, including HRK, MCL1, BCL2A1 and NOL3 which interact
with the intrinsic or mitochondrial pathway. Additionally, the
differences observed regarding the preferred apoptosis pathway
between cblB and cblC patients were further conﬁrmed using different
apoptosis stimulus. Therefore, cblB patients' cell lines presented a
higher rate of apoptosis compared to the other cell lineswhen all were
treated with staurosporine, showing a higher sensitivity to this death
activator of the intrinsic or mitochondrial pathway. The relative
contribution of mitochondrial oxidative phosphorylation to the
supply of metabolic energy in the cell could be responsible for the
different cell death response to staurosporine between different cell
lines [40]. However, TNF-α induced a higher apoptosis rate in cblC celllines which possibly are more sensitive to the extrinsic pathway
activation.
Cell lines from patients with cblC disorder present a gene
expression proﬁling that suggests a higher rate of apoptosis compared
to cblB ﬁbroblasts. Among the pro-apoptotic genes with altered
expression, 9 were overexpressed in the cblB group versus 18 in the
cblC one, and 11 were under-expressed in the cblB group versus 3 in
cblC. Our ﬁndings are consistent with our previous studies in which
cblC patients' ﬁbroblasts showed the highest ROS content and the
highest percentage of apoptotic cells compared to the other patients'
(mut, cblA and cblB) and controls' cell lines [24,25]. Moreover, cblC
patients were also characterized by a higher expression of pro-
apoptotic proteins of the BCL-2 family (HRK, BIK, BAX) and CIDE
domain family (CIDEA, CIDEB), and by signiﬁcant levels of anti-
apoptotic proteins of BCL-2, IAP and TRAF families. The increased rate
of apoptosis in cblC patients' ﬁbroblasts and their pattern of gene
expression dominated by pro-apoptotic members might up-regulate
the anti-apoptotic molecules through a compensatory response. In
addition, our results proved that CASP3 was down-regulated in both
patients' groups, specially in cblC patients. The expression pattern of
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however the amount of protein in these cell lines may be sufﬁcient to
trigger its activation, as we have previously observed [24].
Two pro-apoptotic genes which are members of the p53 family
(TP53 and TP53BP2) were under-expressed in both cblB and cblC
patients' ﬁbroblasts. Regulation of p53 function is highly complex and
occurs at different levels. The tumor suppressor p53 can induce
apoptosis through both the two main apoptotic pathways activating
the transcription of genes that promote this process. Our results
indicate that apoptosis observed in cblB and cblC cell lines may not be
p53-dependent given that those genes were down-regulated. It is also
interesting to note that p53 can modulate the balance between
glycolytic and respiratory pathways through the actions of various
proteins [41], and that cells that lack functional p53 show an
enhanced glycolysis activity and lower oxygen consumption by
mitochondrial respiration [42]. Likewise, we propose that in cblB
and cblC patients the ﬂux through the glycolytic pathway may be
increased due to a mitochondrial dysfunction, as it has been described
in Huntington's disease, a progressive neurodegenerative disorder
[43], and in cancer [44]. In order to test this hypothesis, complemen-
tary studies are planned to be performed.
OHCbl treatment provokes a reduction in ROS levels [25] and also
in stress-kinases activation in patients' cell lines. In addition, the
mRNA apoptotic expression has been ameliorated when MMACHC
function was partially restored in retroviral infected patients'
ﬁbroblasts. Our results suggest that the MMACHC defect in cblC
patients is at least in part responsible for the increased ROS and
apoptosis levels observed in these patients' cell lines. It is important to
note that there is a weak correlation between genotype and ROS and
apoptosis phenotype given the variability of these levels among cell
lines carrying the same mutations. This fact could be explained by
other unidentiﬁed regulatory, genetic and/or epigenetic factors
[45,46], such as unlinked genes that could be involved in the OHCbl
response and/or in other processes related to oxidative stress and
apoptosis that can act as external modulators.
Since both cblB patients with isolated MMA and cblCwith MMAHC
accumulate methylmalonic acid, the built up of homocysteine in cblC
patients could be responsible for the differences observed in the
apoptosis process in both groups of patients. In addition, the fact that
ROS levels and p38 activation were also elevated in cblE and CBS cell
lines with homocystinuria support this hypothesis. Apoptosis may be
enhanced in these groups of patients by the presence of homo-
cysteine, as it has been described in brain endothelial cells [47,48],
osteoblasts and vascular endothelial cells [49,50]. Further analysis will
provide a deeper insight into the effect of homocysteine in the
activation of apoptosis and/or ROS production, as well as on the
association of apoptosis with the irreversible neurological damage
characteristic of these patients, which persists and in some cases can
be even fatal despite the treatment [25,51–53]. Based on the evidence
from stress oxidative studies in other human diseases, it might be
predicted that antioxidants may be a good therapeutic option. We
were able to prevent the apoptosis activation in vitro using Tiron®,
suggesting that the generation of superoxide contributes critically to
the basal apoptosis levels in the cell lines studied. Further studies
using other antioxidants will allow to establish the effectiveness of
these compounds in the overall improvement of the patients' health
status.
5. Conclusions
In summary, we provide the ﬁrst evidence that p38 and JNK MAPK
pathways are activated in patients' cell lines with defects in cobalamin
metabolism, and we also demonstrate that there is a different pattern
of apoptotic gene expression between cblB and cblC cells. Moreover,
all the data reported herein support our previous observations in cblC
cell lines that present the highest rate of apoptosis, and that theintrinsic or mitochondrial apoptosis pathway is activated in cblB
ﬁbroblasts. These observed differences could be explained by the
toxic built up of homocysteine in cblC, since methylmalonic acid is
accumulated in both groups of patients. Therefore, the loss of
MMACHC function in cblC patients might be partially responsible for
the oxidative stress and apoptosis processes observed in these cell
lines. These studies may have clinical impact because they support the
potential of diminishing intracellular ROS and oxidative-stress-
induced apoptosis as a novel strategy for the treatment of these
devastating diseases. Eventually, patients diagnosed by the neonatal
screening could beneﬁt greatly from this new therapeutic approach.
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